EPI 589

Drug Profile

EPI 589

Alternative Names: EPI-589

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edison Pharmaceuticals
  • Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules
  • Mechanism of Action Antioxidants; NAD(P)H dehydrogenase (quinone) modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 09 Jun 2015 Edison Pharmaceuticals plans a phase IIa trial for Parkinson's disease in USA (NCT02462603)
  • 08 Jun 2015 Edison Pharmaceuticals plans a phase IIa trial for Amyotrophic lateral sclerosis in USA (NCT02460679)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top